Drug Profile

GC 1109

Alternative Names: BARYTHRAX; GC-1109

Latest Information Update: 17 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Green Cross
Developer GC Biopharma
Class Anthrax vaccines
Mechanism of Action Immunostimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Registered Anthrax

Most Recent Events

09 Apr 2025 Registered for Anthrax (Prevention) in South Korea (IM)
05 Nov 2023 Preregistration for Anthrax (Prevention) in South Korea (IM)
19 Dec 2022 Green Cross Corporation completes a phase II trial in Anthrax(Prevention) in South Korea(IV) (NCT01624532)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com